Answers are grounded in this paper and cite their sources.
High durable responses to anti-PD-1 immune checkpoint inhibitor (ICI) have been demonstrated in cutaneous squamous cell carcinoma (cSCC). We evaluated the prognosis of patients with advanced cSCC following early cessation of ICI due to response to treatment. This was a retrospective study of patients with advanced, unresectable cSCC who had discontinued ICI following response, prior to completion of 24 months of planned therapy. The endpoints included disease-specific survival (DSS), progression-free survival (PFS) and overall survival (OS). Of the 306 patients during 2020-2024, 55 (18%) patients had discontinued treatment following a response. The median time on treatment was 8 months (95% CI 7-11 months) At a median follow-up of 24 months (95%CI 21-27 months), 5 patients (9%) had developed progressive disease (PD) and 7 patients (13%) had died, 1 due to PD and 6 due to non-malignant etiology. At 24 months, the estimated rate of DSS was 97%, PFS 78% and OS 83%. Prognosis was not significantly affected by baseline characteristics. The PFS was significantly longer for patients ceasing therapy secondary to response without treatment limiting toxicities compared with treatment limiting toxicities (NR vs 27 months [95%CI 23-31]; P=0.027). Rechallenge with ICI for PD was associated with a response in 4 out of 5 evaluable patients. A low incidence of PD following cessation of ICI was observed, with high 24-month DSS, PFS and OS rates, suggesting patients may be able to safely cease therapy following response to reduce potential toxicity and burden of treatment. • Response to immunotherapy in advanced cutaneous squamous cell carcinoma is durable. • Outcomes from early discontinuation of treatment following response are unknown. • Early treatment discontinuation following response correlated significantly with survival. • Patients who did progress were successfully treated with rechallenge immunotherapy. • Immunotherapy maybe safely discontinued following response, limiting treatment burden.
No takes yet. Share an insight, caveat, or question.
Ladwa et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: